SHR-1316
Small Cell Lung Cancer
Key Facts
About Jiangsu Hengrui Medicine
Jiangsu Hengrui Medicine's mission is to advance healthcare through high-quality, innovative medicines, solidifying its position as China's largest and most valuable pharmaceutical company. Its key achievements include building a massive pipeline of 719 drug candidates, successfully launching multiple blockbuster oncology drugs in China, and establishing international R&D footprints. The company's strategy centers on aggressive investment in proprietary R&D, a dual-track approach of 'innovation + internationalization,' and dominating key therapeutic areas like oncology while expanding into metabolic, autoimmune, and neurological diseases.
View full company profileTherapeutic Areas
Other Small Cell Lung Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| IMX101 | Imunexus Therapeutics | Preclinical |
| LNTH-2503 | Lantheus Medical Imaging | Phase 1 |
| Small Cell Lung Cancer (SCLC) FFPE | The MT Group | N/A - Service |
| Immunomodulator Platform | OmniCyte | Pre-clinical |
| Discovery Program | Disco Pharmaceuticals | Discovery |
| SCLC Program | Arcellx | Discovery |
| APG-1252 (Pelcitoclax) | Ascentage Pharma Group | Phase 1/2 |
| zocilurtatug pelitecan (ZL-1310) | Zai Lab | Phase 3 |